The Role of fosA in Challenges with Fosfomycin Susceptibility Testing of Multispecies Klebsiella pneumoniae Carbapenemase-Producing Clinical Isolates-Reference-Cited by-同舟云学术

The Role of fosA in Challenges with Fosfomycin Susceptibility Testing of Multispecies Klebsiella pneumoniae Carbapenemase-Producing Clinical Isolates

Published:2019-10 Issue:10 Volume:57 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Elliott Zachary S.¹²,Barry Katie E.²,Cox Heather L.¹²,Stoesser Nicole³⁴^ORCID,Carroll Joanne⁵,Vegesana Kasi⁶,Kotay Shireen²,Sheppard Anna E.³⁴,Wailan Alex²,Crook Derrick W.³⁴⁷,Parikh Hardik⁸,Mathers Amy J.²⁵^ORCID

Affiliation:

1. Department of Pharmacy Services, University of Virginia Health System, Charlottesville, Virginia, USA

2. Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia Health System, Charlottesville, Virginia, USA

3. Modernizing Medical Microbiology Consortium, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford University, Oxford, United Kingdom

4. NIHR Health Protection Research Unit in Healthcare Associated Infection and Antimicrobial Resistance, University of Oxford in partnership with Public Health England, Oxford, United Kingdom

5. Clinical Microbiology, Department of Pathology, University of Virginia Health System, Charlottesville, Virginia, USA

6. Health Information & Technology, University of Virginia Health System, Charlottesville, Virginia, USA

7. NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom

8. School of Medicine Research Computing, University of Virginia, Charlottesville, Virginia, USA

Abstract

With multidrug-resistant (MDR) Enterobacterales on the rise, a nontoxic antimicrobial agent with a unique mechanism of action such as fosfomycin seems attractive. However, establishing accurate fosfomycin susceptibility testing for non- Escherichia coli isolates in a clinical microbiology laboratory remains problematic. We evaluated fosfomycin susceptibility by multiple methods with 96 KPC-producing clinical isolates of multiple strains and species collected at a single center between 2008 and 2016.

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.00634-19

Reference31 articles.

1. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States. Centers for Disease Control and Prevention, Atlanta, GA.

2. Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections

3. In Vitro Activity of Fosfomycin against bla KPC -Containing Klebsiella pneumoniae Isolates, Including Those Nonsusceptible to Tigecycline and/or Colistin

4. Intravenous fosfomycin—back to the future. Systematic review and meta-analysis of the clinical literature

5. Intravenous Fosfomycin (ZTI-01) for the Treatment of Complicated Urinary Tract Infections (cUTI) Including Acute Pyelonephritis (AP): Results from a Multi-center, Randomized, Double-Blind Phase 2/3 Study in Hospitalized Adults (ZEUS)

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The prevalence, antimicrobial resistance and molecular genetic characteristics of fosfomycin-resistant Klebsiella pneumoniae isolated from raw milk;International Dairy Journal;2024-12

2. Fosfomycin susceptibility testing and resistance mechanisms in Enterobacterales in South Africa;African Journal of Laboratory Medicine;2024-03-19

3. Raising the alarm: fosfomycin resistance associated with non-susceptible inner colonies imparts no fitness cost to the primary bacterial uropathogen;Antimicrobial Agents and Chemotherapy;2024-01-10

4. Guidelines for Antibacterial Treatment of Carbapenem-Resistant Enterobacterales Infections;Infection & Chemotherapy;2024

5. Application of Next-Generation Sequencing to Enterobacter Hormaechei Subspecies Analysis during a Neonatal Intensive Care Unit Outbreak;Children;2023-10-16